Immunohistochemical Expression of SOX2 and EpCAM in Colorectal Cancer and its Precancerous lesions | ||||
| Zagazig University Medical Journal | ||||
| Article 29, Volume 30, Issue 2, March and April 2024, Page 522-532 PDF (1.42 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2022.145296.2587 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Aziza E. Abdelrahman   1; Asmaa Abdullatif2
| ||||
| 1Pathology department, faculty of medicine, zagazig university, Egypt | ||||
| 2pathology department, faculty of medicine, zagazig university | ||||
| Abstract | ||||
| BACKGROUND: There is an actual need for novel prognostic biomarkers to improve colorectal cancer (CRC) patient’s outcome. OBJECTIVES: To evaluate SOX2 and EpCAM immunohistochemical expression in 40 cases of CRC and premalignant lesions. METHODS: The immunohistochemical expression was done according to Envision polymer technique on 40 cases of CRC besides twenty specimens of premalignant lesions. Furthermore, their clinicopathological significance was statistically investigated. RESULTS: High SOX2 immunoexpression was detected in 57.5 % of CRC cases and was significantly associated with tumor size, high tumor grade, LVI, LN involvement, advanced tumor stage, and tumor budding (P=0.04, P | ||||
| Keywords | ||||
| colorectal carcinoma; SOX2; EpCAM; prognostic factor | ||||
|
Statistics Article View: 127 PDF Download: 33 |
||||
